Lack of Association between Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) -1722T/C (rs733618) Polymorphism and Cancer Risk: From a Case-Control Study to a Meta-Analysis
Background The association between cytotoxic T-lymphocyte antigen 4 (CTLA-4) gene -1722T/C polymorphism (rs733618) and cancer has been widely assessed, and a definitive conclusion remains elusive. We first performed a hospital based case-control study to measure this association of esophageal cancer with CTLA-4 -1722T/C polymorphism in Han Chinese population, and then carried out a meta-analysis to obtain a comprehensive evaluation for this issue. Methodology/Principal Findings This case-control study involved 629 esophageal squamous cell carcinoma (ESCC) cases and 686 age and gender well matched cancer-free controls. PCR-LDR (polymerase chain reaction-ligase detection reactions) method was used to identify genotypes. Meta-analysis was conducted by STATA (v12.0) software. This case-control study showed no significant difference in the genotype and allele distributions of CTLA-4 -1722T/C polymorphism between esophageal cancer cases and control subjects, in accord with the findings of the further meta-analysis in all genetic models. Evidence of large heterogeneity was observed among all eligible studies in the recessive model. Further subgroup analyses by ethnicity, cancer type and system, detected null associations in this meta-analysis. Conclusion This case-control study and the further meta-analysis, failed to identify the association between CTLA-4 -1722T/C polymorphism and cancer risk.
References
[1]
Jemal A, Bray F (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90. doi: 10.3322/caac.20107
[2]
Liu L, Zhong R, Wei S, Yin JY, Xiang H, et al. (2011) Interactions between genetic variants in the adiponectin, adiponectin receptor 1 and environmental factors on the risk of colorectal cancer. PLoS One 6: e27301. doi: 10.1371/journal.pone.0027301
[3]
Reeves GK, Pirie K, Green J, Bull D, Beral V, et al. (2012) Comparison of the effects of genetic and environmental risk factors on in situ and invasive ductal breast cancer. Int J Cancer 131: 930–937. doi: 10.1002/ijc.26460
[4]
Zhang Y, Zhang J, Deng Y, Tian C, Li X, et al. (2011) Polymorphisms in the cytotoxic T-lymphocyte antigen 4 gene and cancer risk: a meta-analysis. Cancer 117: 4312–4324. doi: 10.1002/cncr.25979
[5]
Welsh MM, Applebaum KM, Spencer SK, Perry AE, Karagas MR, et al. (2009) CTLA4 variants, UV-induced tolerance, and risk of non-melanoma skin cancer. Cancer Res 69: 6158–6163. doi: 10.1158/0008-5472.can-09-0415
[6]
Sun T, Zhou Y, Yang M, Hu Z, Tan W, et al. (2008) Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 68: 7025–7034. doi: 10.1158/0008-5472.can-08-0806
[7]
Hu L, Liu J, Chen X, Zhang Y, Liu L, et al. (2010) CTLA-4 gene polymorphism +49 A/G contributes to genetic susceptibility to two infection-related cancers-hepatocellular carcinoma and cervical cancer. Hum Immunol 71: 888–891. doi: 10.1016/j.humimm.2010.05.023
[8]
Scheipers P, Reiser H (1998) Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 crosslinking. Proc Natl Acad Sci U S A 95: 10083–10088. doi: 10.1073/pnas.95.17.10083
[9]
Vandenborre K, Van Gool SW, Kasran A, Ceuppens JL, Boogaerts MA, et al. (1999) Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation. Immunology 98: 413–421. doi: 10.1046/j.1365-2567.1999.00888.x
[10]
Ueda H, Howson JM, Esposito L, Heward J, Snook H, et al. (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423: 506–511. doi: 10.1038/nature01621
[11]
Geng R, Song F, Yang X, Sun P, Hu J, et al.. (2013) Association between cytotoxic T lymphocyte antigen-4 +49A/G, -1722T/C, and -1661A/G polymorphisms and cancer risk: a meta-analysis. Tumour Biol.
[12]
Chen ZJ, Zhao H, He L, Shi Y, Qin Y, et al. (2011) Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet 43: 55–59. doi: 10.1038/ng.732
[13]
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151: : 264–269, W264.
Hadinia A, Hossieni SV, Erfani N, Saberi-Firozi M, Fattahi MJ, et al. (2007) CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. J Gastroenterol Hepatol 22: 2283–2287. doi: 10.1111/j.1440-1746.2007.04862.x
[16]
Erfani N, Razmkhah M, Talei AR, Pezeshki AM, Doroudchi M, et al. (2006) Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet Cytogenet 165: 114–120. doi: 10.1016/j.cancergencyto.2005.07.020
[17]
Li H, Fu ZK, Wang LH, Li DL, Wu N, et al. (2008) [Association of cytotoxic T lymphocyte antigen-4 gene polymorphisms with susceptibility to breast cancer]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 24: 282–284.
[18]
Li D, Zhang Q, Xu F, Fu Z, Yuan W, et al. (2012) Association of CTLA-4 gene polymorphisms with sporadic breast cancer risk and clinical features in Han women of northeast China. Mol Cell Biochem 364: 283–290. doi: 10.1007/s11010-012-1228-8
[19]
Qi YQ SL, Cui JY, Ji LS (2012) Polym orphism of CTLA-4 gene prom oter region and extron region in gastric cancer. Chinese Clinical Oncolog 17: 828–831.
[20]
Song JQ XB, Li R, Li C, Wu YH (2006) Association of the CTLA4 promoter region polymorphism with gastric cancer. Chinese Journal of Experimental Surgery 23: 1373–1374.
[21]
Jiang L, Luo RY, Zhang W, Wang LR, Wang F, et al. (2011) [Single nucleotide polymorphisms of CTLA4 gene and their association with human cervical cancer]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 28: 313–317.
[22]
Khaghanzadeh N, Erfani N, Ghayumi MA, Ghaderi A (2010) CTLA4 gene variations and haplotypes in patients with lung cancer. Cancer Genet Cytogenet 196: 171–174. doi: 10.1016/j.cancergencyto.2009.09.001
[23]
Rahimifar S, Erfani N, Sarraf Z, Ghaderi A (2010) ctla-4 gene variations may influence cervical cancer susceptibility. Gynecol Oncol 119: 136–139. doi: 10.1016/j.ygyno.2010.06.006
[24]
Bharti V, Mohanti BK, Das SN (2013) Functional genetic variants of CTLA-4 and risk of tobacco-related oral carcinoma in high-risk North Indian population. Hum Immunol 74: 348–352. doi: 10.1016/j.humimm.2012.12.008
[25]
Jones KA, Kadonaga JT, Rosenfeld PJ, Kelly TJ, Tjian R (1987) A cellular DNA-binding protein that activates eukaryotic transcription and DNA replication. Cell 48: 79–89. doi: 10.1016/0092-8674(87)90358-8
[26]
Zhu JM, Li BK, Chen GM, Feng CC, Cen H, et al. (2013) CTLA-4 -1722T/C polymorphism and systemic lupus erythematosus susceptibility: a meta-analysis involving ten separate studies. Immunol Invest 42: 91–105. doi: 10.3109/08820139.2012.724752
[27]
Chen SL, Deng F, Jiang F, Liu JJ, Meng W (2012) [Correlation between CTLA-4 gene polymorphism and systemic lupus erythematosus: a meta-analysis]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 28: 1320–1323.
[28]
Liu J, Zhang H (2013) -1722T/C polymorphism (rs733618) of CTLA-4 significantly associated with systemic lupus erythematosus (SLE): a comprehensive meta-analysis. Hum Immunol 74: 341–347. doi: 10.1016/j.humimm.2012.12.009
[29]
Zhai JX, Zou LW, Zhang ZX, Fan WJ, Wang HY, et al. (2013) CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis. Mol Biol Rep 40: 5213–5223. doi: 10.1007/s11033-012-2125-7
